FDC Intraday Analysis...

FDC Share Price

Open 216.00 Change Price %
High 217.25 1 Day -4.70 -2.18
Low 208.60 1 Week 7.60 3.75
Close 210.50 1 Month 26.60 14.46
Volume 49847 1 Year -0.80 -0.38
52 Week High 235.00
52 Week Low 163.25
FDC Important Levels
Resistance 2 218.52
Resistance 1 215.21
Pivot 212.12
Support 1 205.79
Support 2 202.48
NSE INDIA Most Active Stocks
JPASSOCIAT 18.75 -2.60%
RCOM 13.60 -2.51%
BHEL 92.85 4.74%
HDIL 61.55 0.24%
PRAJIND 105.95 19.99%
SUZLON 13.60 -0.37%
JAICORPLTD 161.05 1.77%
IDEA 96.10 -2.39%
IBREALEST 212.50 -0.26%
PNB 186.50 -1.43%
More..
NSE INDIA Top Gainers Stocks
PRAJIND 105.95 19.99%
MTEDUCARE 68.60 19.93%
APTECHT 395.85 19.45%
PRECOT 101.95 19.03%
SPECIALITY 167.00 17.11%
RAJRAYON 0.35 16.67%
NAGREEKEXP 51.55 16.63%
DIAPOWER 18.45 15.67%
PITTILAM 78.35 15.39%
SIS 1032.15 14.63%
More..
NSE INDIA Top Losers Stocks
KSERASERA 0.15 -25.00%
LCCINFOTEC 0.35 -12.50%
NEULANDLAB 1133.60 -10.75%
PATSPINLTD 32.60 -9.94%
PANORAMUNI 9.35 -9.22%
COMPINFO 26.25 -7.89%
RUCHISOYA 24.75 -6.25%
QUESS 858.00 -6.17%
GLOBALVECT 184.15 -6.02%
LITL 0.80 -5.88%
More..

FDC Limited (NSE: FDC)

FDC Technical Analysis 4
As on 23rd Nov 2017 FDC Share Price closed @ 210.50 and we RECOMMEND Buy for LONG-TERM with Stoploss of 194.38 & Strong Buy for SHORT-TERM with Stoploss of 188.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
FDC Target for November
1st Target up-side 203.12
2nd Target up-side 211.58
3rd Target up-side 220.04
1st Target down-side 178.98
2nd Target down-side 170.52
3rd Target down-side 162.06
FDC Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
Bullish
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Grater Then SIGNAL Line Bullish
RSI (14) RSI is 65.19 Sideways
MFI (14) MFI is Above 80 Over Bought
CCI (20) CCI is Above 100 Over Bought
WILLIAM %R (14) William %R is -49.59 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Long Buy 200.69
10 Day Avg Volume Traded -68.76 % Less then 10 Day Average Volume
FDC Other Details
Segment EQ
Market Capital 5328551936.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.fdcindia.com
FDC Address
FDC
142-48, S. V. Road
Jogeshwari (West)
Mumbai, 400 102
India
Phone: 91 22 2678 0652
Fax: 91 22 2678 8123
Interactive Technical Analysis Chart FDC Limited ( FDC NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on FDC Limited
FDC Business Profile
FDC, formerly FairDeal Corporation, is engaged in bulk drugs, formulations and food products. It has a presence in numerous therapeutic segments such as anti-infectives, dermatologicals, respiratory, haematinics and ophthalmics. Its plant in Roha manufactures pharma dosage forms, food products and bulk drugs for anti-rheumatic, anti-asthmatics, opthalmic and ENT segments. These bulk drugs are either exported (more than 80% of the production) or formulated at the company`s plants in Jogeshwari and Waluj. FDC, which also manufactures Electral and oral rehydration salts (ORS), has a market share of 1.32%. The company has a manufacturing plant in Goa for manufacture of tablet dosage forms. FDC is in the process of setting up additional facilities to manufacture sterile ophthalmic dosage forms at Waluj by adding one more form-fill-seal (FFS) machine. The said plant has quality systems of international GMP standards, which will enable the company to enter the US generic market and also cater to the expanding domestic demand. FDC`s subsidiaries are FDC Holdings; Netherlands BV; FDC International, UK; and FDC Inc, New Jersey, USA. Fair Deal Corporation Pharmaceutical SA is its joint venture entity. The company is in the process of developing a Concept Product that offers photo-protection in various ocular conditions including dry eyes. It has completed filing of four ANDAs for ophthalmic dosage forms and has plans to file further four ANDAs for molecules going off patentin the near future. The company plans to design and develop economically viable sequences for manufacture of APIs with domestic and export potential. It plans to implement backward integration to create and formulate substitutes for imported raw materials. There is a focus on filing process and product patents along with the development of various sustained release dosage forms and modern/future drug delivery systems. The company also desires to develop new products for the domestic, export markets and also for social causes apart from developing nutraceuticals and extensions to the range of food products. The current market capitalization stands at Rs 1,805.01 crore.The company has reported a standalone sales of Rs 228.72 crore and a Net Profit of Rs 49.07 crore for the quarter ended September 2013. The company management includes Mohan A Chandavarkar - Chairman & Managing Director, Nandan M Chandavarkar - Joint Managing Director, Ashok A Chandavarkar - Director, Ameya A Chandavarkar - Director, Girish C Sharedalal - Director, Satish S Ugrankar - Director, Rahim H Muljiani - Director, Nagam H Atthreya - Director, Vinod G Yennemadi - Director. The Registered office is at B-8, MIDC Industrial Estate, Waluj, Aurangabad District,Maharashtra - 431136 and corporate office is at 142-148, S.V. Road, Jogeshwari (W), Mumbai - 400102.